Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 184.87M P/E - EPS this Y 16.40% Ern Qtrly Grth -
Income -46.45M Forward P/E -5.04 EPS next Y 70.60% 50D Avg Chg -9.00%
Sales 81k PEG - EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book 3.15 EPS next 5Y - 52W High Chg -54.00%
Recommedations 1.90 Quick Ratio 10.42 Shares Outstanding 29.78M 52W Low Chg 35.00%
Insider Own 2.13% ROA -32.79% Shares Float 29M Beta 0.20
Inst Own 26.92% ROE -91.92% Shares Shorted/Prior 2.15M/1.71M Price 7.00
Gross Margin 100.00% Profit Margin - Avg. Volume 222,606 Target Price 25.40
Oper. Margin -61,645.68% Earnings Date Aug 12 Volume 107,766 Change -1.96%
About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for people with relapsed and refractory acute myeloid leukemia for bone marrow transplant; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.

Actinium Pharmaceuticals, Inc. News
07/25/24 Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
07/25/24 Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
07/11/24 3 Under-$10 Biotech Stocks That Could Make You Rich
07/02/24 3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
06/20/24 Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
06/18/24 Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
06/17/24 Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
06/17/24 Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
06/14/24 Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
06/11/24 Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
06/10/24 Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
06/10/24 Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
06/07/24 Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
06/04/24 Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
05/15/24 Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
05/14/24 Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
05/14/24 3 Cheap Biotech Stocks to Buy Now: May 2024
05/13/24 Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
05/07/24 Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
04/18/24 Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
ATNM Chatroom

User Image luzongeezer Posted - 51 minutes ago

$ATNM Gettin all monsoony here....

User Image Karmic Posted - 5 hours ago

$ATNM 1. Iomab-ACT is a low dosage Iomab-B. 2. Both should have similar, if not the same, manufacturing process. 3. Iomab-ACT received FDA IND approval which would have manufacturing information. The rest you can figure out using syllogism.

User Image FactsPlease99 Posted - 9 hours ago

$IOVA $ATNM RNA , what a mistake I made selling RNA way back in single digits however a 5 billion market cap trading @ $48 with one drug in phase 3, 100 mill shares outstanding is 86% IO. And then there is ATNM 200 MILL MARKET CAP with phase 3, 29 million shares outstanding and only 26% IO owned. Also IOVA 2.5 Bill market cap 89% IO with FDA approved drugs.

User Image Ferric Posted - 9 hours ago

@gooddoggie @bobbychef @fwilkerson $QDTE paid me today35 cents per share on Monday $AIPI will pay me $1.4799 per share I am totally clearing 5K this month ✌️ Plus, I have enough $ATNM shares, that when this gets bought out...I can retire from stocktwits

User Image resume777 Posted - 9 hours ago

$ATNM Vanguard and Fidelity Funds still holding. Net effect of these 7/26/2024 reports was +16,980 shares.

User Image GwilliamG Posted - 10 hours ago

$ATNM — uh oh…people might actually need to watch what they say now…ahem….EFHuffin

User Image Theflash88 Posted - 11 hours ago

$ATNM I’ll take $50 any day.

User Image gooddoggie Posted - 11 hours ago

$ATNM @bobbychef @fwilkerson My mission this weekend, should I choose to accept it - Chicken and Dumplings! I always loved it and now found this recipe for those of us who are basically a disaster in the kitchen! https://www.allrecipes.com/recipe/218562/super-easy-chicken-and-dumplings/

User Image gooddoggie Posted - 11 hours ago

$ATNM Big day Tuesday, rest of the week hanging on.

User Image englishkaren Posted - 11 hours ago

$ATNM 19,132 @ $7.82 16:00 hrs

User Image Alpha_4 Posted - 11 hours ago

$ATNM Seth what’s your plan man? Going to take on the big dogs on your own? What in the fuck

User Image AAVIE Posted - 11 hours ago

$ATNM

User Image BxxZ Posted - 11 hours ago

$ATNM 343k shares traded through DP's today.....

User Image Pickerbefore Posted - 12 hours ago

$ATNM management took big paychecks this week and did not do their job. They are about to take more options too for missing 3 deadlines for filing the BLA almost two years after the data dropped. Look up Bad Management in a dictionary and find Seth’s picture. Shame in the BOD.

User Image Pickerbefore Posted - 13 hours ago

$ATNM stock managed well by Seth and MM

User Image tmodicaa Posted - 14 hours ago

@AAVIE I mean in a way that a BO is attractive. Ultimately trying to say that with $ATNM stagnant movement during this increase in Radiopharm BOs what is the problem . CEO or pipeline ?

User Image johnny4cures Posted - 15 hours ago

$ATNM vol has been rising past 3 days and this is good when it's sp is up as well. Very good fundamentals backdrop along with positive upcoming events is an even better sign. If I were the ceo of a big pharma, it's a great time to buy here.

User Image Theflash88 Posted - 15 hours ago

$ATNM Not sure what it’s going to take other than a buyout to move this stock.. my 2nd largest position.. I see a lot of upside! I’m holding patiently…?

User Image tjm1 Posted - 15 hours ago

$ATNM They use the reference Optimistic and expanding opportunity yet HC Wainright held their previous target $50.............."Optimistic Buy Rating for Actinium Pharmaceuticals Amid Iomab-ACT Advancements and Expanding Market Opportunities"

User Image resume777 Posted - 16 hours ago

@herwilagn @gwilliamg $ATNM there is a Bristol thread I posted this morning that goes more indepth about pre/post earnings call impacts. One thing that the Bristol EC confirmed today. 4Q2024: After EC in October, 2 M&A announced in December and stock price for BMY -$1. It was also during the holiday period between Christmas and New Years; not many traders. 1Q2024: Negative EPS due to $18B M&A resulted in -$4 pps 2Q2024: Positive EPS without any M&A announcement resulted in +$4 pps. July 31: TRP conference San Diego. August 1: Bristol dividend distribution. The time period between now and Actinium's 10-Q (mid-August) is of most interest for both Bristol and Gilead.

User Image GwilliamG Posted - 17 hours ago

$ATNM -- just couldn't help myself. We are four weeks into the quarter and still no update on 1H milestones. I just view this as confirmation that there needs to be more "activism" here....

User Image tjm1 Posted - 17 hours ago

$ATNM HC Wainwright issued a $50 target prior to yesterdays sickle cell PR. Why wouldn't the updated target price increase rather than remain the same?

User Image resume777 Posted - 17 hours ago

$ATNM they would likely debt finance any deal. The best part, earlier in the year Chris (CEO) said interest rates would not have a significant impact on deals.

User Image resume777 Posted - 17 hours ago

@noggindog $ATNM during the call, their CFO said $7B on hand from the quarter.

User Image noggindog Posted - 17 hours ago

$ATNM Today's BMY earnings look very good. Although I cannot find current cash on hand, it was over $9M at last quarterly report. Would they spend half on acquisition of ATNM?

User Image Investfaithfully Posted - 18 hours ago

$ATNM

User Image resume777 Posted - 19 hours ago

$ATNM Johnson & Johnson. https://stocktwits.com/resume777/message/579707688

User Image resume777 Posted - 19 hours ago

$ATNM Novartis. https://stocktwits.com/resume777/message/579792956

User Image resume777 Posted - 19 hours ago

$ATNM RayzeBio platform on the back-half of the decade. The robust IND engine in the backhalf of the decade. State of the art manufacturing facility. RZE-101. GEP-NETs, modest commercial opportunity. Actinium-based platform, potential efficacy across solid tumor treatment. SCLC.

User Image resume777 Posted - 19 hours ago

$ATNM Bristol Myers. https://stocktwits.com/resume777/message/579948755

Analyst Ratings
HC Wainwright & Co. Buy Jul 26, 24
HC Wainwright & Co. Buy Jun 17, 24
HC Wainwright & Co. Buy May 21, 24
Stephens & Co. Overweight May 14, 24
HC Wainwright & Co. Buy May 2, 24
Cantor Fitzgerald Overweight Apr 30, 24
HC Wainwright & Co. Buy Apr 29, 24
HC Wainwright & Co. Buy Apr 1, 24
Cantor Fitzgerald Overweight Apr 1, 24